These findings were in agreement with our in vitro study, suggesting that CAFs promoted lung cancer growth through the METTL3-mediated m6A modification of RAC3 mRNA, and activated metastasis-related genes and the AKT pathway. The gene discussed is RAC3; the disease is lung carcinoma.